Nektar Therapeutics (NKTR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Nektar Therapeutics (NKTR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH4344D
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Nektar Therapeutics (Nektar) is a biopharmaceutical company. It carries out discovery and development of a pipeline of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. Nektar's technology platformns offers a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The company's products focuses on various therapeutic areas, including, cancer, pain, anti-infectives, anti-viral and immunology among others. Its research and development activities involve peptides, small molecule drugs, and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics (NKTR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Nektar Therapeutics Enters into Agreement with Takeda Pharma 11

Bristol-Myers Squibb Company Enters into Agreement with Nektar Therapeutics 11

Licensing Agreements 12

Eli Lilly to Enter into Licensing Agreement with Nektar Therapeutics 12

Nektar Therapeutics Enters into Licensing Agreement with Daiichi Sankyo Europe for Onzeald 13

Equity Offering 15

Nektar Therapeutics Prices Public Offering of Shares for USD175.5 Million 15

Nektar Therapeutics Completes Public Offering Of Shares For USD124.6 Million 16

Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For USD225 Million 17

Debt Offering 19

Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 19

Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For USD125 Million 20

Asset Transactions 21

RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 21

Nektar Therapeutics-Key Competitors 23

Key Employees 24

Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

May 09, 2017: Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 27

Mar 01, 2017: Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 30

Nov 03, 2016: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2016 32

Aug 03, 2016: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016 34

May 03, 2016: Nektar Therapeutics Reports Financial Results for the First Quarter of 2016 36

Mar 01, 2016: Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results 37

Corporate Communications 39

Jun 02, 2016: Nektar Therapeutics Announces Executive Management Promotions 39

Clinical Trials 40

Apr 18, 2016: Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor Repertoire and T Cell Tumor Infiltration 40

Feb 01, 2016: Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43

List of Figures

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Nektar Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Nektar Therapeutics, Deals By Therapy Area, 2011 to YTD 2017 9

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Nektar Therapeutics Enters into Agreement with Takeda Pharma 11

Bristol-Myers Squibb Company Enters into Agreement with Nektar Therapeutics 11

Eli Lilly to Enter into Licensing Agreement with Nektar Therapeutics 12

Nektar Therapeutics Enters into Licensing Agreement with Daiichi Sankyo Europe for Onzeald 13

Nektar Therapeutics Prices Public Offering of Shares for USD175.5 Million 15

Nektar Therapeutics Completes Public Offering Of Shares For USD124.6 Million 16

Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For USD225 Million 17

Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 19

Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For USD125 Million 20

RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 21

Nektar Therapeutics, Key Competitors 23

Nektar Therapeutics, Key Employees 24

Nektar Therapeutics, Other Locations 26

Nektar Therapeutics, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Nektar Therapeutics, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16300
Site License
USD 500 INR 32600
Corporate User License
USD 750 INR 48900

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com